Stock Events

EKF Diagnostics 

GBX30.2
21
-GBX0.66-2.14% Today

Statistics

Day High
30.76
Day Low
30.1
52W High
-
52W Low
-
Volume
305,927
Avg. Volume
-
Mkt Cap
141.11M
P/E Ratio
31.1
Dividend Yield
3.89%
Dividend
1.17

Upcoming

Dividends

3.89%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
2.94%
1Y Growth
N/A

Earnings

24SepExpected
Q4 2021
Q2 2022
Q4 2022
Q2 2023
Q4 2023
Q1 2024
Next
0
0.73
1.46
2.19
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EKF.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; Ultracrit, a hematocrit device; DiaSpect Hemoglobin T analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240 and Excel analyzers; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-parties. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
Show more...
CEO
Mr. Julian Huw Baines M.B.E.
Employees
317
Country
GB
ISIN
GB0031509804
WKN
000622434

Listings